STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes
Acute myeloid leukemia Acute myeloid leukemia: (uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells.
Myelodysplastic Syndromes (MDS)
Genome sequencing in the management of myelodysplastic syndromes and related disorders
Myeloid neoplasms originate from the clonal proliferation of hematopoietic stem cells stem cells: Cells in the body that develop into other cells. There are two main sources of stem cells.
Diagnosis of myelodysplastic syndromes: the classic and the novel
The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the
Treatment of high-risk myelodysplastic syndromes
Myelodysplastic syndrome (MDS) is considered to be a heterogeneous myeloid malignancy with a common origin in the hematopoietic stem cell compartment and is generally divided into lower- and higher-risk forms. While the treatment goals for lower-risk MDS are to decrease transfusion requirements and transformation into acute leukemia, the major aims for higher-risk MDS are to prolong survival and ultimately cure the patient.
Treatment of lower-risk myelodysplastic syndromes
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT
Original Publication Date
Article Source
External Web Content
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis…
How is transfusion dependence evolving in anemia treatment in MDS?
Original Publication Date
Article Source
External Web Content
A roundtable discussion on anemia management in myelodysplastic syndromes. Featuring moderator Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center; Amy DeZern, MD, MHS, Johns Hopkins Medicine; Tiffany Tanaka, MD, of the University of California San…
Jane Biehl: Moving Slower and Slower After Myelodysplastic Syndrome
Original Publication Date
Article Source
External Web Content
I have honestly been frustrated lately. I am slowing down increasingly, and it has even become noticeable to others. I wrote an article in November about how nice it was to slow down and smell the roses. But now it seems like too much. In my previous life (before cancer), I moved…
What are some of the new therapies discussed at ASH 2024?
Original Publication Date
Article Source
External Web Content
A roundtable discussion on anemia management in myelodysplastic syndromes featuring moderator Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center; Amy DeZern, MD, MHS, Johns Hopkins Medicine; Tiffany Tanaka, MD, of the University of California San…
Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications
Original Publication Date
Article Source
External Web Content
Key Points The ICC and WHO5 differently classify 64% of TP53-mutated disease due to distinct criteria for multihit TP53 mutations and TP53-mutated AML. MDS with a single TP53 mutation and CK is similar to MDS with biallelic TP53 abnormalities, whereas TP53-mutated AML is distinct…